Top news of the week: 29.04.2021.
Startups
Covid-19 Devastated Some Industries But Accelerated AI Use By Companies Across The Country
Covid-19 devastated some industries but accelerated AI use by companies across the country.
Hospital Costs, Not Drug Prices, Are Out Of Control
Hospital Costs, Not Drug Prices, Are Out Of Control Now that we have a steady supply of Covid-19 vaccines that will allow for all Americans to be vaccinated by this summer, politicians are ...
Covid Lockdowns Prevented Other Infections. Is That Good?
The “hygiene hypothesis” says early contact with microbes trains our immune systems. But what happens after a year of distancing?
Liberating Founders and Investors From Narrative Bias
We’re drawn to stories. We understand the world through stories – both the narratives we read, and those we create and develop for ourselves. It’s the very power – the unreasonable ...
Pfizer buys infectious disease biotech Amplyx
The deal is another sign of Pfizer's interest in infectious disease beyond COVID-19, following the pharma's participation in an industry investment fund.
GV hires industry veteran Lynch to coach biotech CEOs, identify new investments
GV has hired serial biotech chairman Dan Lynch as its first executive venture partner. The appointment positions Lynch to serve as a coach and adviser to executives at GV’s portfolio ...
Health challenges need predictable healthcare investment policies. Japan’s example shows why
Japan could work together with the global biotech and life sciences sector to become a world leader – offering lessons for other countries.
Ex-Lilly R&D lead Bilenker launches new cancer biotech with Novartis' oncology R&D head Engelman
Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new solutions to old oncology ...